Kite Pharma, a biotech developing a cancer drug that utilizes the immune system, filed on Monday with the SEC to raise up to $115 million in an initial public offering. The Santa Monica, Ca-based company, which was founded in 2009, plans to list on the NASDAQ under the symbol KITE. Kite Pharma initially filed confidentially on April 4, 2014. Jefferies, Credit Suisse, Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
